Coronavirus Disease: A Review of a New Threat to Public Health

Kamleshun Ramphul ¹, Stephanie G. Mejias ²

¹. Pediatrics, Shanghai Jiao Tong University School of Medicine/Shanghai Xin Hua Hospital, Shanghai, CHN ². Family Medicine/Pediatrics/Internal Medicine, The University Iberoamericana Unibe School of Medicine/Robert Reid Cabral Children’s Hospital, Santo Domingo, DOM

Corresponding author: Kamleshun Ramphul, adramphul@hotmail.com

Abstract

In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods.

Introduction And Background

Over the last few decades, the world has seen the existence of new viruses that posed serious threats to global health. In late December 2019, several patients in Wuhan, China started reporting symptoms that resembled pneumonia. A new virus was identified and initially called the 2019 novel coronavirus (2019-nCoV). The World Health Organization (WHO) eventually changed the name of the virus to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The disease it causes has been named coronavirus disease 2019 (COVID-19). The SARS-CoV is a positive-stranded RNA virus that originates from the Coronaviridae family. Other viruses from the same family include the severe acute respiratory syndrome coronavirus (SARS-CoV), which appeared in 2002, and Middle East respiratory syndrome coronavirus (MERS-CoV), which was reported in 2012 [2]. Since the virus is spreading worldwide, on March 11, 2020, the WHO officially described the COVID-19 outbreak as a pandemic.

Review

Epidemiology

As of March 10, 2020, the WHO has reported that there are 113,702 confirmed cases globally, and 4,012 deaths have been registered; 71% of all confirmed cases (80,924) and 78% of all deaths related to COVID-19 (3140) are from China and its territories. Since the first reported case in Wuhan, 109 other countries have declared that they have at least one confirmed case of

How to cite this article
Ramphul K, Mejias S G (March 15, 2020) Coronavirus Disease: A Review of a New Threat to Public Health. Cureus 12(3): e7276. DOI 10.7759/cureus.7276
COVID-19. The WHO has officially classified China as a "very high risk" region for COVID-19 [3].

### Mainland China and territories

The province of Hubei, which includes Wuhan, currently has the highest confirmed number of cases and deaths in mainland China (67,760 cases and 3,024 deaths). Among the regions in China that have crossed the four-digit mark, Guangdong, Henan, Zhejiang, and Hunan each have 1,353, 1,272, 1,215, and 1,018 cases, respectively (Table 1). The second-highest number of deaths was reported in Guangdong with 22 cases.

| Province      | Confirmed cases | Deaths |
|---------------|-----------------|--------|
| Hubei         | 67,760          | 3,024  |
| Guangdong     | 1,353           | 8      |
| Henan         | 1,272           | 22     |
| Zhejiang      | 1,215           | 1      |
| Hunan         | 1,018           | 4      |
| Anhui         | 990             | 6      |
| Jiangxi       | 935             | 1      |
| Shandong      | 758             | 6      |
| Jiangsu       | 631             | 0      |
| Chongqing     | 576             | 6      |
| Sichuan       | 539             | 3      |
| Heilongjiang  | 481             | 13     |
| Beijing       | 429             | 8      |
| Shanghai      | 342             | 3      |
| Hebei         | 318             | 6      |
| Fujian        | 296             | 1      |
| Guangxi       | 252             | 2      |
| Shaanxi       | 245             | 1      |
| Yunnan        | 174             | 2      |
| Hainan        | 168             | 6      |
| Guizhou       | 146             | 2      |
| Tianjin       | 136             | 3      |
| Shanxi        | 133             | 0      |
| Province             | Confirmed Cases | Deaths |
|----------------------|-----------------|--------|
| Liaoning             | 125             | 1      |
| Gansu                | 124             | 2      |
| Hong Kong SAR        | 115             | 3      |
| Jilin                | 93              | 1      |
| Xinjiang             | 76              | 3      |
| Ningxia              | 75              | 0      |
| Inner Mongolia       | 75              | 1      |
| Taipei and environs  | 45              | 1      |
| Qinghai              | 18              | 0      |
| Macao SAR            | 10              | 0      |
| Xizang               | 1               | 0      |
| **Total**            | **80,924**      | **3,140** |

**TABLE 1: Number of confirmed cases and deaths linked with COVID-19 in China as of March 10, 2020 (reported by the WHO)**

SAR: special administrative region; WHO: World Health Organization

**Outside China**

While South Korea and Iran were initially the two most affected countries outside China, the number of cases started to rise in Italy in late February and, as of March 10, 2020, Italy is the country outside China with the highest number of total confirmed cases (9,172) (Table 2).
### Table 2: Number of confirmed cases and deaths related to COVID-19 outside of China as of March 10, 2020 (reported by the WHO)

| Country                      | Number of confirmed cases | Deaths |
|------------------------------|---------------------------|--------|
| South Korea                  | 7,513                     | 54     |
| Japan                        | 514                       | 9      |
| Italy                        | 9,172                     | 463    |
| France                       | 1,402                     | 30     |
| Germany                      | 1,138                     | 2      |
| Spain                        | 1,024                     | 28     |
| Iran                         | 7,161                     | 237    |
| USA                          | 472                       | 19     |
| Other countries (excluding China) | 3,686                     | 23     |

**Who:** World Health Organization

---

**What is severe acute respiratory syndrome coronavirus 2?**

SARS-CoV-2 is a positive-sense, single-stranded RNA virus. The SARS-CoV-2 virion is about 50-200 nm in diameter and consists of four main structural proteins; spike (S), envelope (E), membrane (M), and nucleocapsid (N) [4]. The S protein allows the virus to bind to the host’s cell membrane. The angiotensin-converting enzyme 2 (ACE2) receptors on host cells have been found to be the target of S proteins. It then undergoes structural changes to fuse with the host, and this eventually allows viral genes to enter the host cell [5-7].

Genomic comparison has shown that the SARS-CoV-2 has an 80% resemblance to Rhinolophus sinicus bat and 96% resemblance with the Rhinolophus affinis bat [8,9]. One research team found that one sample of the virus had a 99% genomic similarity with pangolins and suggested that the animal may be an intermediate host to the virus [10,11].

According to the Centers for Disease Control and Prevention (CDC), the transmission of SARS-CoV-2 occurs mostly person-to-person via respiratory droplets within a range of 180 cm. The virus can also be transmitted if a person touches a mucosal surface after touching an object with the virus on it [12].

**What are the clinical symptoms of COVID-19?**

While the incubation period of the virus was initially thought to be 14 days, multiple cases have been reported with shorter timelines. A study by Guan et al. calculated the median incubation period to be four days with a lower interquartile range of two days and an upper interquartile range of seven days. In their study, the most common finding on imaging was ground-glass opacity on CT (56.4%) [13]. They found that 45.8% had a fever on admission and 88.7% during hospitalization. The cough was also a common symptom and was seen in 67.8% of patients. The
Chinese Center for Disease Control and Prevention has reported that 87% of confirmed cases were in adults aged between 30 and 79 years. The mortality and case fatality rate increased with increasing ages; the case fatality rate was 8% in patients aged between 70 and 79 years while it was 15% in those aged 80 years or more [14].

A study involving 10 children showed that most presented with fever (80%) while 60% had cough [15]. All children presented with mild symptoms and they all recovered. The study also reported that the patients had prolonged virus shedding in the respiratory tract and feces, even during their convalescent stage. A second study involved nine infected infants aged 1-11 months. Four out of the nine patients presented with fever; one infant had no symptoms but was tested positive for the virus. None of the infants needed mechanical ventilation or had to be admitted in intensive care [16].

How are patients tested for SARS-CoV-2?

Samples from the upper respiratory tract are used to test for the virus. Polymerase chain reaction (PCR) is used to identify their viral RNA. If the test is positive, the diagnosis of SARS-CoV-2 is confirmed. Negative tests with a strong suspicion, such as clinical symptoms or exposure, can be repeated using samples from other respiratory sites [17,18].

Treatment of COVID-19

Multiple antiviral regimens are being tried to help patients with severe symptoms of the virus. Lopinavir and ritonavir have been used in some clinical trials. Lim et al. reported that the drugs helped their patient as he improved clinically and viral loads decreased significantly [19]. Four COVID-19 patients were recruited by Wang et al. for a study in Shanghai, China, and they also improved with a combined therapy of lopinavir and ritonavir [20]. In Singapore, confirmed cases that were hospitalized were also given the combined antiviral therapy of lopinavir and ritonavir. While some patients reported improvement in their symptoms, four patients developed nausea, vomiting, or diarrhea, and three patients showed elevated liver function test results [21].

Several other treatment options such as Remdesivir (Gilead Sciences, Foster City, CA), peptide (EK1), neuraminidase inhibitors, chloroquine, and arbidol have also been suggested [22]. There are multiple research teams trying to investigate a possible vaccine for the virus. The role of the spike protein in the viral infectivity and pathogenesis is a possible preventive target [23].

How to prevent COVID-19?

The CDC recommends multiple steps to prevent the transmission and risk of SARS-CoV-2. Frequent hand washing lasting at least 20 seconds by using soap and water is advised. Hand sanitizers with at least 60% alcohol can also be used as an alternative. The public has also been told to avoid touching mucosal surfaces such as the mouth and the nose with hands that have not been washed. Anyone showing symptoms of the virus should try to seek appropriate medical help. They should also limit their exposure to other unaffected people and cover their noses and mouths when coughing or sneezing. They are also advised to wear a facemask if they present with symptoms. Frequent disinfection and cleaning are advised for groups that are at risk of contracting the virus [24].

Conclusions

The SARS-CoV-2 is spreading across the world at an alarming rate. The elderly and immunocompromised patients are most vulnerable to the mortal repercussions of the virus. While some treatment protocols have shown some promise, there is at present no confirmed
cure for the virus and no vaccine has been developed. With proper preventive measures, the virus can be contained and the population protected.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Centers for Disease Control and Prevention: coronavirus disease 2019 (COVID-19) - situation summary. (2020). Accessed: March 11, 2020: https://www.cdc.gov/coronavirus/2019-ncov/situation-summary.html.
2. Centers for Disease Control and Prevention: human coronavirus types . (2020). Accessed: March 11, 2020: https://www.cdc.gov/coronavirus/types.html.
3. WHO: coronavirus disease (COVID-19) situation reports . (2020). Accessed: March 11, 2020: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
4. Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016/S0140-6736(20)30211-7
5. Letko M, Marzi A, Munster V: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020, Accessed: March 15, 2020: https://www.nature.com/articles/s41564-020-0688-y. 10.1038/s41564-020-0688-y
6. Gralinski LE, Menachery VD: Return of the Coronavirus: 2019-nCoV. Viruses. 2020, Accessed: March 15, 2020: https://www.mdpi.com/1999-4915/12/2/135/htm. 10.3390/v12020135
7. Lu R, Zhao X, Li J, et al.: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020, 395:565-74. 10.1016/S0140-6736(20)30251-8
8. Zhou P, Yang XL, Wang XG, et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-3. 10.1038/s41586-020-2012-7
9. Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019 . (2020). Accessed: March 11, 2020: https://www.biorxiv.org/content/10.1101/2020.02.07.939207v1.
10. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B: Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020, 12:9. 10.1038/s41568-020-0075-9
11. Identification of a pangolin niche for a 2019-nCoV-like coronavirus through an extensive meta-metagenomic search. (2020). Accessed: March 11, 2020: https://www.biorxiv.org/content/10.1101/2020.02.08.959660v2.
12. Centers for Disease Control and Prevention: how COVID-19 spreads . (2020). Accessed: March 11, 2020: https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html.
13. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China . N Engl J Med. 2020, 10.1056/NEJMoa2002032
14. Wu Z, McGoogan JM: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020, 10.1001/jama.2020.2648
15. Cai J, Xu J, Lin D, et al.: A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020, 10.1093/cid/ciaa198
16. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ: Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA. 2020, 10.1001/jama.2020.2131
17. Centers for Disease Control and Prevention: persons evaluated for 2019 novel coronavirus — United States, January 2020. (2020). Accessed: March 11, 2020: https://www.cdc.gov/mmwr/volumes/69/wr/mm6906e1.htm?s_cid=mm6906e1_x.

18. Coronavirus disease 2019 (COVID-19). (2020). Accessed: March 11, 2020: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19#H2325386707.

19. Lim J, Jeon S, Shin HY, et al.: Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020, 35:e79. 10.3346/jkms.2020.35.e79

20. Wang Z, Chen X, Lu Y, Chen F, Zhang W: Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020, 10.5582/bst.2020.01030

21. Young BE, Ong SWX, Kalimuddin S, et al.: Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020, 10.1001/jama.2020.3204

22. Lu H: Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020, 10.5582/bst.2020.01020

23. National Institutes of Health: novel coronavirus structure reveals targets for vaccines and treatments. (2020). Accessed: March 11, 2020: https://www.nih.gov/news-events/nih-research-matters/novel-coronavirus-structure-reveals-targets-vaccines-treatments.

24. Centers for Disease Control and Prevention: coronavirus disease 2019 (COVID-19) - how to protect yourself. (2020). Accessed: March 11, 2020: https://www.cdc.gov/coronavirus/2019-ncov/about/prevention.html.